ASTRAZENECA in Croatian translation

• astrazeneca

Examples of using Astrazeneca in English and their translations into Croatian

In support of that application, Astrazeneca submitted clinical data from two Phase II studies.
U prilog tome zahtjevu Astrazeneca je dostavila kliničke podatke nastale provedbom dvaju ispitivanja II. stadija.

It is not intended to provide practical advice on how to use Pandemic influenza vaccine H5N1 AstraZeneca.
Svrha sažetka nije davati praktične savjete o primjeni Cjepiva protiv pandemijske influence H5N1 AstraZeneca.

Pandemic influenza vaccine H5N1 AstraZeneca contains live,
Cjepivo protiv pandemijske influence H5N1 AstraZeneca sadrži živi atenuirani(oslabljeni)

The name of the medicine was changed to Pandemic influenza vaccine H5N1 AstraZeneca on 24 May 2017.
Naziv lijeka promijenjen je u Cjepivo protiv pandemijske influence H5N1 AstraZeneca 24. svibnja 2017.

effective use of Pandemic influenza vaccine H5N1 AstraZeneca?
učinkovita primjena Cjepiva protiv pandemijske influence H5N1 AstraZeneca?

More information on how AstraZeneca complies with its data privacy obligations can be found in our internal global privacy standards.
Više informacija o tome kako AstraZeneca ispunjava svoje obveze povezane sa zaštitom osobnih podataka možete pronaći u našim internim globalnim standardima zaštite osobnih podataka.

marked with“OLAPARIB 50 mg” and the AstraZeneca logo in black ink.
oznakom"OLAPARIB 50 mg" i logom tvrtke AstraZeneca otisnutima crnom tintom.

Pandemic influenza vaccine H5N1 AstraZeneca(Pandemic influenza vaccine H5N1 Medimmune)(reassortant influenza virus(live attenuated)…)- Summary of product characteristics- J07BB03.
Pandemic influenza vaccine H5N1 AstraZeneca(Pandemic influenza vaccine H5N1 Medimmune)(reassortant influenza virus(live attenuated)…)- Sažetak opisa svojstava lijeka- J07BB03.

AstraZeneca AB local representative of marketing authorisation holder: AstraZeneca d.o.o.
Tvrtke AstraZeneca AB lokalni predstavnik nositelja odobrenja: AstraZeneca d.o.o.

Company name: AstraZeneca d.o.o.
Ime kompanije: AstraZeneca d.o.o.

AstraZeneca paid 520 million dollars to settle claims it illegally marketed the antipsychotic Seroquel.
AstraZeneca je platila odštetu od 520 milijuna dolara kako bi se nagodila zbog optužbi da je ilegalno reklamirala antipsihotik Seroquel.

Manufacturer: AstraZeneca UK Limited Silk Road Business Park Macclesfield,
Proizvođač: AstraZeneca UK Limited Silk Road Business Park Macclesfield,

Although Pandemic influenza vaccine H5N1 AstraZeneca might increase wheezing in children aged 1 to 2 years,
Iako Cjepivo protiv pandemijske influence H5N1 AstraZeneca može pojačati piskanje pri disanju u djece u dobi od 1 do 2 godine,

This showed that antibodies against Pandemic influenza vaccine H5N1 AstraZeneca increased substantially when vaccinated adults came into contact with the virus again.
To pokazuje da su se protutijela na Cjepivo protiv pandemijske influence H5N1 AstraZeneca značajno povećala kad su cijepljene odrasle osobe ponovo došle u kontakt s virusom.

For more information about prevention of influenza with Pandemic influenza vaccine H5N1 AstraZeneca, read the package leaflet(also part of the EPAR)
Više informacija o suzbijanju gripe Cjepivom protiv pandemijske influence H5N1 AstraZeneca pročitajte u uputi o cjepivu(također dio EPAR-a),

Pandemic influenza vaccine H5N1 AstraZeneca(Pandemic influenza vaccine H5N1 Medimmune)(reassortant influenza virus(live attenuated)…)- Conditions
Pandemic influenza vaccine H5N1 AstraZeneca(Pandemic influenza vaccine H5N1 Medimmune)(reassortant influenza virus(live attenuated)…)- Uvjeti

For practical information about using Pandemic influenza vaccine H5N1 AstraZeneca, patients should read the package leaflet
Praktične informacije o primjeni Cjepiva protiv pandemijske influence H5N1 AstraZeneca bolesnici trebaju pročitati u uputi o cjepivu,

Pandemic influenza vaccine H5N1 AstraZeneca is a vaccine developed to protect children aged between 12 months
Cjepivo protiv pandemijske influence H5N1 AstraZeneca cjepivo je razvijeno za zaštitu djece u dobi između 12 mjeseci

You are not permitted to re-sell and/or otherwise commercialise all or any part of any AstraZeneca RSS Feed and/or any AstraZeneca Content.
Nije Vam dopušteno preprodavati ni na neki drugi način komercijalizirati cijeli ili dio bilo kojeg RSS kanala društva AstraZeneca i/ili bilo kojeg sadržaja društva AstraZeneca.

Moreover, the argument that Astrazeneca would appear to have put forward- to the effect that it has not in fact had the time
Nadalje, što se tiče argumenta koji Astrazeneca izgleda ističe, to jest da u stvarnosti nije imala vremena niti prilike distribuirati lijek